Compare G & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | BIO |
|---|---|---|
| Founded | 1997 | 1952 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.0B |
| IPO Year | 2007 | N/A |
| Metric | G | BIO |
|---|---|---|
| Price | $38.96 | $300.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $50.33 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.4M | 234.7K |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.10 | N/A |
| Revenue | ★ $5,009,342,000.00 | $2,557,500,000.00 |
| Revenue This Year | $8.47 | $1.50 |
| Revenue Next Year | $6.96 | $2.23 |
| P/E Ratio | $14.23 | ★ N/A |
| Revenue Growth | ★ 7.39 | N/A |
| 52 Week Low | $37.49 | $211.43 |
| 52 Week High | $56.76 | $358.40 |
| Indicator | G | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 20.78 | 40.62 |
| Support Level | $43.87 | $289.11 |
| Resistance Level | $44.77 | $302.59 |
| Average True Range (ATR) | 1.24 | 9.53 |
| MACD | -0.58 | -1.67 |
| Stochastic Oscillator | 1.74 | 27.47 |
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.